News

Going forward, the center is expected to create employment opportunities for scientists and lab technicians. Joseph Sammut, chief officer at Malta Enterprise and a council member of the

CytoCore, the developer of cost-effective products used in the practice of cytology for the detection and diagnosis of cancer and cancer related diseases, has reported that the study

The analysis showed that this advanced diagnostic test consistently identified more than 50% of hormone receptor positive early-stage breast cancer patients in AP countries as having low Recurrence

The application for approval of additional indication for type 2 diabetic incipient nephropathy for Micardis tablets was submitted by Nippon Boehringer Ingelheim on June 2006. The decision for

Celegene claimed that CITRE would bring together key parties from government, industry and academia. The collaboration’s main objective is to minimise the gap between basic scientific research and

Earlier, in January 2010, Vion has filed a SPA with the FDA related to a randomised Phase II/III trial of Onrigin in combination with low-dose Ara-C (LDAC) in

With this cooperation, Kemwell and Boehringer Ingelheim will provide customers with technology from Europe along with the benefit of low cost manufacturing from India. Process technology will originate

Bapineuzumab is a compound under development by Pfizer and Janssen Alzheimer Immunotherapy, a Johnson & Johnson subsidiary in which Elan holds a minority equity interest. Elan said that

In May 2009 DSM and MCC already announced the signing of a memorandum of understanding for the intended swap. For both companies the businesses they will add to